CurrentBlue Cross Blue Shield - OklahomaPolicy CPCPLAB011

ANA/ENA Testing

Laboratory reimbursement and medical necessity criteria for ANA, ENA, dsDNA and related connective tissue disease serologic testing for Blue Cross Blue Shield - Oklahoma members and providers.

Policy Summary

PayerBlue Cross Blue Shield - Oklahoma

PolicyANA/ENA Testing

Policy CodePolicy CPCPLAB011

Change TypeNew policy

Effective DateNov. 1, 2022

Next Review Date

Key ActionOrder ANA/ENA/dsDNA testing only when there is high clinical suspicion of autoimmune disease and provide supporting clinical documentation.

SourceLink

POLICY UPDATE CHANGES

New policy implemented.

1.0policy version

Nov. 1, 2022Plan effective date

4/yrdsDNA limit

10+references

Coverage and Medical Necessity Criteria

inv-01: Medically Necessary / Reimbursable Testing

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

General ANA/ENA/dsDNA reimbursement criteria: Testing reimbursable when clinical suspicion of autoimmune disease is high based on signs, symptoms, and other factors; ENA panel testing reimbursable in patients with abnormal or raised antibody titer or abnormal immunological findings in serum with clinical correlation to the appropriate autoimmune disorder; dsDNA testing reimbursable up to four (4) times per year after an initial positive ANA test with clinical correlation; testing of specific antibodies when ANA is negative/low positive reimbursable only for Anti-Jo-1 in a unique myositis subset and Anti-SSA in the setting of lupus or Sjögren's syndrome.dsDNA <=4 per year after initial positive ANA

Clinical correlation with signs, symptoms, and abnormal immunologic findings is required.

inv-02: Not Reimbursable

Not reimbursable / excluded testing:

Not reimbursable conditions: Monitoring disease with ANA testing or ANA titers; ANA and/or ENA testing for individuals with nonspecific symptoms (e.g., fatigue, musculoskeletal pain) without other symptoms suggestive of SLE; ANA/ENA testing during wellness visits or general encounters without abnormal findings; testing of specific antibodies in the absence of a positive ANA test in all other situations; use of cell-bound complement activation products (e.g., AVISE Lupus); any other proprietary serum biomarker panels with algorithms/index scores for diagnosis of SLE or connective tissue diseases (e.g., Avise CTD).

These situations are considered not reimbursable per the policy.

Cell-bound complement activation products and proprietary multianalyte serum biomarker panels are excluded from reimbursement. Specifically, the policy states that the use of cell-bound complement activation products (e.g., AVISE Lupus) is not reimbursable for the diagnosis of systemic lupus erythematosus (SLE), and that any other serum biomarker panel testing with proprietary algorithms and/or index scores (e.g., Avise CTD) is not reimbursable for all applications related to SLE or connective tissue disease diagnosis.

Routine monitoring of disease using ANA testing or ANA titers is not reimbursable. Additionally, ANA and/or ENA testing for individuals with nonspecific symptoms (for example, fatigue or musculoskeletal pain) without other findings suggestive of SLE is not reimbursable, and ANA/ENA testing performed during wellness visits or general encounters without abnormal findings is also not reimbursable.

Indications for Covered Testing

inv-13: High clinical suspicion of autoimmune disease based on signs, symptoms, and other factors.

Covered indications when clinical suspicion is strong:

High clinical suspicion of autoimmune disease: Clinical presentation with signs, symptoms, and other factors strongly suggestive of an autoimmune connective tissue disease (e.g., features consistent with SLE, Sjögren's, myositis) supporting initial ANA testing and further serologic evaluation.

ENA testing appropriate when there is an abnormal or raised ANA titer or abnormal immunologic serum findings; Anti-Jo-1 and Anti-SSA may be ordered in the limited situations specified.

Coding Guidance and Frequency Limits

Coding guidance and claims submissionmixed

No codes listed

dsDNA testing frequency after initial positive ANA

Frequency limitTesting of dsDNA reimbursable up to four (4) times per year after an initial positive ANA test with clinical correlation.

ApplicabilityApplies only after an initial positive ANA and when there is clinical correlation with signs/symptoms of autoimmune disease.

Documentation expectationMedical record should support clinical correlation to justify repeated dsDNA testing within the year.

dsDNA testing — frequency limit

Maximum frequencyUp to four (4) dsDNA tests per year following an initial positive ANA.

ConditionRequires an initial positive ANA test and ongoing clinical correlation for repeat testing.

Coverage stanceReimbursable within the stated limit; testing beyond four per year not supported by this policy.

Provider Responsibilities and Billing Considerations

Note

Plan/product review required

Not all requirements apply to each product. Providers should review plan documents (Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents) for eligible coverage and applicable benefit/contract language.

Documentation Required

Documentation and submission expectations

Providers are responsible for submission of accurate documentation of services performed and for coding claims using valid HIPAA-approved code sets (CPT, HCPCS, ICD-10, NDC, DRG, etc.). Claims are subject to code edits and clinical/contract review; BCBS OK may request additional documentation and has discretion in interpreting and applying this policy.

Submit claims using industry-standard coding guidelines (AMA, CPT, CMS NCCI, UB Editor, etc.)
Be prepared to provide additional documentation upon request

Denial Risk

Common denial triggers

Claims for testing may be denied when testing is ordered for nonspecific symptoms or without clinical correlation to an autoimmune disorder. Testing during wellness visits or general encounters without abnormal findings is not reimbursable.

ANA and/or ENA testing for nonspecific symptoms (eg, fatigue, musculoskeletal pain) without other suggestive signs of SLE — not reimbursable
Testing during wellness visits or general encounters without abnormal findings — not reimbursable

Prior Authorization

(Unnamed provider-action callout)

Prior authorization/medical necessity should be confirmed where required by the member's plan. Reimbursement is generally limited to situations with strong clinical suspicion or abnormal findings (for example: initial positive ANA with clinical correlation; ENA panel when abnormal antibody titers or immunologic findings correlate with disease; dsDNA up to 4 times/year after initial positive ANA). Proprietary multi-biomarker panels and cell‑bound complement tests (eg, AVISE Lupus, Avise CTD) are not reimbursable for diagnosis of SLE or connective tissue diseases.

ENA panel testing reimbursable when abnormal antibody titer or immunologic findings correlate with clinical disease
dsDNA testing reimbursable up to 4 times/year after an initial positive ANA and clinical correlation
Anti‑Jo‑1 and Anti‑SSA testing reimbursable only in specific clinical contexts (myositis subset; lupus or Sjögren's, respectively)
Cell‑bound complement activation products (eg, AVISE Lupus) and proprietary biomarker/index panels (eg, Avise CTD) — not reimbursable

Ordering and Prior Authorization Requirements

Step Therapy

Order testing only with high clinical suspicion and clinical correlation

Review plan documents for coverage specifics and order testing only when clinical suspicion for autoimmune disease is high and there is clinical correlation with abnormal immunologic findings.

ENA panels should be ordered when a raised antibody titer or abnormal immunologic serum findings are present with clinical correlation.
dsDNA testing may be ordered up to four times per year after an initial positive ANA with clinical correlation.
Specific antibody testing when ANA is negative is reimbursable only in limited situations (e.g., Anti‑Jo‑1 for certain myositis, Anti‑SSA for lupus or Sjögren's).

Not Covered Services

The following tests and panels are not covered / not reimbursable: cell-bound complement activation products (e.g., AVISE Lupus), Avise CTD, and other proprietary multianalyte serum biomarker panels that use proprietary algorithms or index scores for diagnosis of SLE or connective tissue diseases. These proprietary panels are excluded for all applications per this policy.

Definitions

ANA / ENA / dsDNA — definitions

ANAAntinuclear antibody (ANA) testing used to screen for autoimmune connective tissue diseases; reimbursable when clinical suspicion is high based on signs, symptoms, and other factors.

ENAExtractable nuclear antigen (ENA) panel testing (e.g., nRNP, SS-A, SS-B, Sm, RNP, Scl-70, Jo-1) — reimbursable when there is an abnormal, raised antibody titer or abnormal immunologic serum findings with clinical correlation.

dsDNADouble-stranded DNA antibody testing used in evaluation of systemic lupus erythematosus (SLE); reimbursable up to four (4) times per year after an initial positive ANA test with clinical correlation.

Background

Antinuclear antibody (ANA) testing and extractable nuclear antigen (ENA) panels are screening and diagnostic tools used in the evaluation of suspected autoimmune connective tissue diseases such as systemic lupus erythematosus (SLE), Sjögren's syndrome, and inflammatory myopathies. These tests should be interpreted with clinical correlation: ANA testing may be reimbursable when clinical suspicion is high based on signs and symptoms, and ENA panel testing (for antibodies such as nRNP, SS‑A, SS‑B, Sm, RNP, Scl‑70, Jo‑1) may be reimbursable in patients with an abnormal or raised antibody titer or other abnormal immunologic serum findings with appropriate clinical correlation. dsDNA testing is addressed separately and may be reimbursable with limits.